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Introduction
CXC chemokines display pleiotropic effects participating
not only in inflammation, but regulating angiogenesis and
metastatic spread in cancer. Platelet factor 4 (PF4) is a
70-amino acid protein belonging to the CXC chemokine
family. PF4 is also known as CXCL4. This chemokine is
released from alpha-granules of activated platelets and
binds with high affinity to heparin-like molecules promot-
ing coagulation.
Megakaryocytes respond to the presence of tumors by
increasing their number in the bone marrow accompa-
nied by increase in the number of platelets in circulation,
causing changes in chemokine balance.
Aim
An attempt was made to get new information about PF4
production in NSCLC and clarify clinical significance of
measuring PF4 level and platelet count.
Patients and methods
Peripheral blood samples were collected from patients
with histologically proven early (n=32) and advanced
(n=12) stage NSCLC, and healthy individuals (n=12).
Complete blood count test to measure concentration of
platelets and exclude acute inflammation was used.
Plasma PF4 levels were determined by ELISA.
Results
Higher levels of PF4 (mean value - 13 pg/mL) observed
in plasma of early stage NSCLC patients compared to
advanced stage NSCLC (mean value - 10,5 pg/mL) and
healthy individuals (mean value - 10,6 pg/mL) (p<0.02).
Thrombocyte level and thrombocytosis found in patients
with advanced NSCLC did not correlate with PF4 levels
(p<0.01).
Conclusion
Many cancers have a complex chemokine network.
Plasma chemokines as PF4 are significant in developing
theories concerning the biology of NSCLC and are
potential key molecules for early detection and treat-
ment of cancer.
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